LOS ANGELES — A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.  In the majority of cases, the cancer disappeared after only three months of treatment, and almost half the patien...